Comparative Pharmacology
Head-to-head clinical analysis: TETRACHEL versus VIBRA TABS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TETRACHEL versus VIBRA TABS.
TETRACHEL vs VIBRA-TABS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Tetracycline antibiotic; inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
100 mg orally twice daily on day 1, then 100 mg orally once daily
None Documented
None Documented
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Terminal elimination half-life: 18-22 hours (single dose); increases to 24-48 hours in renal impairment. Mean half-life after multiple doses: 14-16 hours.
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Renal (40% as unchanged drug via glomerular filtration), biliary/fecal (20-30%, including enterohepatic circulation).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic